ARROWHEAD PHARMACEUTICALS, INC. Noncontrolling Interest, Increase from Subsidiary Equity Issuance
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Noncontrolling Interest, Increase from Subsidiary Equity Issuance of $0 for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity › Noncontrolling Interest Items
us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance · last filed 2026-08-04
- ARROWHEAD PHARMACEUTICALS, INC. noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2026-03-31 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2023-06-30 was $60.00M, a 0.00% change year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2022-09-30 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2022-06-30 was $60.00M.
- ARROWHEAD PHARMACEUTICALS, INC. noncontrolling interest, increase from subsidiary equity issuance for fiscal 2022 was $60.00M.
| Period end | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 3 month | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 6 month | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 9 month | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 12 month |
|---|---|---|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-08-04 | |||
| 2023-06-30 | $60.00M 10-Q · filed 2023-08-07 | |||
| 2022-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | $60.00M derived: sum of 2 quarters · filed 2024-11-26 | $60.00M 10-K · filed 2024-11-26 | |
| 2022-06-30 | $60.00M 10-Q · filed 2022-08-04 | $60.00M 10-Q · filed 2022-08-04 | ||
| 2009-09-30 | $16.30K 10-Q · filed 2014-05-06 | |||
| 2008-09-30 | $1.72M 10-Q · filed 2014-05-06 | |||
| 2007-09-30 | $2.40M 10-Q · filed 2014-05-06 | |||
| 2005-09-30 | $230.09K 10-Q · filed 2014-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |